| 2025-11-06 |
Prokidney |
Results ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 prokidney.com ↗
|
| 2024-06-10 |
Prokidney |
Results ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates prokidney.com ↗
|
| 2023-11-13 |
Prokidney |
Results ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates prokidney.com ↗
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients |
| 2023-01-10 |
Prokidney |
Results ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease prokidney.com ↗
|
| 2022-11-03 |
Prokidney |
Regulatory ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease prokidney.com ↗
We are extremely pleased to announce that the MHRA has granted allowance to ProKidney to open sites in the UK, accepting the proact 1 study protocol that is already underway in the US and Canada. |
| 2022-06-23 |
Prokidney |
Results ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease prokidney.com ↗
The paper, published in Kidney International Reports, describes observed improvements in renal function and a wide array of clinical parameters in patients with moderate to advanced diabetic CKD treated with REACT™. |
| 2022-05-03 |
Prokidney |
Regulatory ProKidney highlights key registrational program elements supporting advancement of REACT® prokidney.com ↗
Furthermore, the FDA accepted ProKidney’s proposal for a long-term 5-year clinical follow-up program for all REACT® injected patients, to be enrolled with patients who have previously received REACT® injections in one or both kidneys. |